CELG Technical Analysis
As of date:11/20/2019
CELG stock price:108.24
CELG 50 DMA:103.23
CELG 200 DMA:95.60
CELG MACD (200-50):-7.63
CELG RSI:51.63
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)51.63
Extremely
Oversold

Also see:
CELG Market Cap History
CELG Shares Outstanding History
CELG YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes

Email EnvelopeFree CELG Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Karat Packaging Breaks Above 200-Day Moving Average - Bullish for KRT
16 hours, 6 minutes ago


Bullish Two Hundred Day Moving Average Cross - PGC
16 hours, 40 minutes ago


ANAB Makes Bullish Cross Above Critical Moving Average
16 hours, 41 minutes ago


Bullish Two Hundred Day Moving Average Cross - CHRD
16 hours, 42 minutes ago


Bullish Two Hundred Day Moving Average Cross - VNOM
16 hours, 42 minutes ago


Gilead Sciences (GILD) Shares Cross Above 200 DMA
16 hours, 59 minutes ago


Bullish Two Hundred Day Moving Average Cross - LFG
17 hours, 9 minutes ago


ESMT Crosses Above Key Moving Average Level
17 hours, 9 minutes ago


KEYS Makes Bullish Cross Above Critical Moving Average
17 hours, 14 minutes ago


SRI Crosses Above Key Moving Average Level
17 hours, 22 minutes ago


Wabash National (WNC) Shares Cross Above 200 DMA
17 hours, 22 minutes ago


WRB Makes Bullish Cross Above Critical Moving Average
17 hours, 22 minutes ago


IGHG Crowded With Sellers
17 hours, 32 minutes ago


JBL Makes Bullish Cross Above Critical Moving Average
17 hours, 32 minutes ago


Bullish Two Hundred Day Moving Average Cross - BHE
17 hours, 32 minutes ago


More Technical Analysis News

CELG Technical AnalysisCELG RSI
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

When researching a stock like Celgene, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from CELG Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for CELG stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
CELG DMACELG MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
 

CELG Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.